home FAQ email sign-up search contact us
Headlines Email Alert Sign-up
HealthCast Calendar
Daily Reports Health Poll Search
Issue Spotlight
<a href="http://www.kaisernetwork.org/daily_reports/rep_index.cfm"><img src="http://www.kaisernetwork.org/images/index_flash_headlines.gif" width="437" height="42" border=0></a>

AIDS 2008: Time to Deliver
Home

Guide to Webcast Coverage

Daily Roundup

Newsmaker Interviews

Mexico City Notebook

Conference Materials

 

This conference only
Related Resources
  > AIDS2008.org

  > Kaiser Family Foundation - KFF.org
  > kaisernetwork.org
  > kaiserEDU.org
  > GlobalHealthFacts.org
  > GlobalHealthReporting.org
  > Previous kaisernetwork.org AIDS Conference Coverage
  > Clinical Care Options

XVII International AIDS Conference: August 3-8, 2008

Late Breaker Track B Session 1
8/7/2008
Mexico City

  Email this webcast

For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance page.

 

Full version:

Video
Transcript
Podcast


Speakers for this session:

  Co-Chairs
 
  A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Pregabalin vs Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy

David Simpson, M.D. (TBC)
Professor of Neurology
Mount Sinai School of Medicine



Abstract
 
  Cost-Effectiveness of Programmatic Models for Provision of Antiretroviral Therapy in Resource-Limited Settings

Joseph Babigumira (TBC)
Doctoral Student, Pharmaceutical Outcomes Research and Policy Program
University of Washington



Abstract
 
  ACTG 5202: Shorter Time to Virologic Failure (VF) with Abacavir/lamivudine (ABC/3TC) than Tenofovir/Emtricitabine (TDF/FTC) as Part of Combination Therapy in Treatment-Naïve Subjects with Screening HIV RNA ³100,000 c/mL

Paul Sax, M.D.
Director, HIV Program
Brigham and Women's Hospital



Abstract
 
  Abacavir/Lamivudine (ABC/3TC) Shows Robust Virologic Responses in ART-Naïve Patients for Baseline (BL) Viral Loads (VL) of ³100,000c/mL and <100,000c/mL by Endpoint Used in ACTG5202

Keith Pappa
GlaxoSmithKline



Abstract
 
  Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction in HIV-Infected Patients Enrolled in the SMART Study

Jens Lundgren
HIV Program
University of Copenhagen



Abstract


 

EMAIL ALERTS
Sign up for email alerts and stay informed about upcoming HealthCasts, and the latest health policy issues, news and events.
 
FAQS
More...
 
CONTACT US
Contact us by email with any comments, problems, suggestions.
Call the kaisernetwork.org Help Desk at 202-347-5270.
...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ......


About Us     Privacy Policy      Help      Site Map